This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Filter 24,016 trials Clear all
Filter by:

Hydroxychloroquine for Treatment of Non-Severe COVID-19

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Covid19
    Covid19
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Hydroxychloroquine tablets

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Hydroxychloroquine tablets

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Namboole COVID-19 treatment unit, Kampala, Uganda

Brief Summary

Currently there are no proven treatments for COVID-19 and current standard therapy is supportive care with oxygen supplementation and treatment of symptoms. Several re-purposed and new drugs have been investigated but none is conclusive for efficacy against COVID-19 .Both Hydroxychloroquine(HCQ) and Chloroquine(CQ) have demonstrated activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and have been investigated in small clinical trials with contradicting reports on their benefits or harm in treatment of COVID-19 .Several authors agree that the use of HCQ for treatment of COVID-19 needs to be assessed in large randomized controlled trials

A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Chronic Hepatitis B
    Chronic Hepatitis B
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: Peginterferon alfa-2b injection, Drug: Peginterferon alfa-2b injection, Drug: TDF, Drug: Peginterferon alfa-2b injection

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Peginterferon alfa-2b injection, Drug: Peginterferon alfa-2b injection, Drug: TDF, Drug: Peginterferon alfa-2b injection

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Beijing Ditan Hospital, Capital Medical University, Beijing, China

Brief Summary

Current clinical practices has shown promising prospects of the therapy strategy of interferon combined with nucleos(t)ides in patients with chronic hepatitis B, but the safety and efficacy has not been fully studied. This study is aimed to exploit the safety and efficacy of the study drug, Peginterferon alfa-2b injection, with nucleos(t)ide (NAs), tenofovir disoproxil fumarate tablets (TDF), in the patients with hepatitis B, who has previously treated with nucleos(t)ides and who are treatment naïve.

Immunocompromised Swiss Cohorts Based Trial Platform

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Immunocompromised Patients
    Immunocompromised Patients
  • Phase Phase 3
    Phase 3
INTERVENTION

Biological: Moderna COVID-19 Vaccine, mRNA-1273 (100 μg), Biological: Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: Moderna COVID-19 Vaccine, mRNA-1273 (100 μg), Biological: Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University Hospital Basel, Basel, Switzerland

Brief Summary

This study is to set up a flexible trial platform using two existing national cohorts of immunocompromised patients (i.e. Swiss HIV Cohort Study [SHCS] and Swiss Transplant Cohort Study [STCS]) to assess the comparative effectiveness and safety of approved SARS-CoV-2 vaccines in immunocompromised patients. This platform will be tested in the frame of an exploratory pilot trial and a framework will be set up to conduct a larger, flexible, randomized controlled trial (RCT) to test approved SARS-CoV-2 vaccines to prevent SARS-CoV-2 infections.

A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Psoriasis
    Psoriasis
  • Phase Phase 3
    Phase 3
INTERVENTION

Biological: CT-P43, Biological: Stelara

Eligibility
  • Ages: 18 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: CT-P43, Biological: Stelara

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Clinical Research Centre, Tartu, Tartu Country, Estonia, Estonia

Brief Summary

This study is a randomized, active-controlled, double-blind, phase 3 study to compare the efficacy and safety of CT-P43 to Stelara in patients with moderate to severe plaque psoriasis.

A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Healthy
    Healthy
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Tralokinumab administered as 1 × X mL with Device A, Device: Tralokinumab administered as 2 × Y mL with Device B

Eligibility
  • Ages: 18 to 55 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: Tralokinumab administered as 1 × X mL with Device A, Device: Tralokinumab administered as 2 × Y mL with Device B

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

LEO Pharma Investigational Site, Berlin, Germany

Brief Summary

The purpose of this trial is to compare the pharmacokinetics (PK), safety, tolerability and immunogenicity of a single dose of 300 mg tralokinumab administered as a 1 × X mL subcutaneous (SC) injection with Device A and 2 × Y mL consecutive SC injections with Device B.

A Study of PRA023 in Healthy Volunteers

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Healthy
    Healthy
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: PRA023, Other: Placebo

Eligibility
  • Ages: 18 to 55 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: PRA023, Other: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Celerion, Lincoln, Nebraska, United States

Brief Summary

This is randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRA023 in healthy volunteers.

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Healthy
    Healthy
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: ALXN2050, Drug: ALXN2050-matching Placebo, Drug: Moxifloxacin, Drug: Moxifloxacin-matching Placebo

Eligibility
  • Ages: 18 to 55 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: ALXN2050, Drug: ALXN2050-matching Placebo, Drug: Moxifloxacin, Drug: Moxifloxacin-matching Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Clinical Trial Site, Tempe, Arizona, United States

Brief Summary

This is a randomized, double-blind, double-dummy, placebo- and positive-controlled parallel study to evaluate the effect of ALXN2050 on the QT interval in healthy adult participants.

Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Venous Thromboembolism, Covid19
    Venous Thromboembolism, Covid19
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: Rivaroxaban 10 MG

Eligibility
  • Ages: 18 to 90 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Rivaroxaban 10 MG

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Science Valley Research Institute, Santo André, São Paulo, Brazil

Brief Summary

The Michelle trial is expected to provide high-quality evidence around the role of extended thromboprophylaxis in COVID-19 and will help guide medical decisions in clinical practice.

Clinical Study of Platelet-rich Plasma Promoting Tendon-bone Healing in Anterior Cruciate Ligament Reconstruction

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Sports Injury
    Sports Injury
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Platelet-Rich Plasma

Eligibility
  • Ages: 15 to 50 Years (Child, Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Platelet-Rich Plasma

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

Anterior cruciate ligament (ACL) injury is a common knee injury, which seriously affects the living ability and sport level of the injured. ACL reconstruction is the main method to treat ACL injury. Due to the reconstructive ligament needs a tendon bone healing and ligament maturation, therefore, in the ACL anatomical study, reconstruction surgery and reconstruction materials under the condition of constant progress, how to improve the ACL reconstruction of tendon bone healing and shorten the time of the ligament mature, improve the clinical effect of ACL reconstruction, has become the focus in the ACL reconstruction. Autologous platelet-rich plasma (PRP) is full of growth factors and bioactive factors, which has the function of promoting tissue healing, anti-inflammatory and analgesic effects. At the same time of anterior cruciate ligament reconstruction, using autologous PRP in the bone channel might promote tendon bone healing and ligament maturing after ACL reconstruction, promote the recovery of proprioception, prevent bone channel expanding, shorten the postoperative recovery time, speed up the patients recovery exercise ability, improve the clinical effect of ACL reconstruction. In this study, patients with ACL injuries were randomly divided into two groups: one group underwent ACL anatomical reconstruction, and the other group underwent ACL anatomical reconstruction with PRP. Various clinical scores, KT-2000, Biodex and imaging tests were used to evaluate the differences in the clinical effects of the two surgical methods in terms of postoperative pain, joint swelling, knee function, joint stability, muscle strength recovery, bone channel expanding, ligament vasinization, and ligament maturation.

Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Tick-Borne Encephalitis
    Tick-Borne Encephalitis
  • Phase Phase 3
    Phase 3
INTERVENTION

Biological: TBE vaccine 0.5 mL, Biological: TBE vaccine 0.25 mL

Eligibility
  • Ages: 1 Year and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Biological: TBE vaccine 0.5 mL, Biological: TBE vaccine 0.25 mL

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Medical Co. LTA PS Clinic, Fukuoka,, Fukuoka, Japan

Brief Summary

The main purpose of this study is to provide safety and immunogenicity data in Japanese participants.